LONDON, February 4, 2014 /PRNewswire/ --
Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract relating to data from the AEGIS Phase III programme of ST10 for the treatment of iron deficiency...